Reuters Health - An novel investigational chemotherapy regimen targeting both a mutated protein called p53 and tumor blood vessels “has complementary and potent antitumor activity and could define a new strategy for suppression of advanced breast cancers,” Dr. Yayun Liang reported at the Department of Defense’s annual Era of Hope breast cancer meeting that just wrapped in Baltimore, Maryland.
